OBJECTIVE： To observe the clinical efficacy and safety of Xuezhikang capsule in the treatment of post-menopause patients with type 2 diabetes and nonalcoholic fatty liver disease and its effect on related indicators. METHODS： 100 patients were randomly divided into observation group （50 cases） and control group （50 cases）. All patients received conventional lifestyle intervention， including diet intervention， controlling body mass and appropriate exercise， etc. Based on it， control group was given Metformin hydrochloride enteric-coated capsule with initial dose of 0.5 g， orally， twice a day， gradually increased to 0.5 g， orally， 3 times a day+Simvastatin tablet with initial dose of 0.5 g， orally， once a day， gradually increased to 40 mg， orally， once a day. Observation group was additionally given Xuezhikang capsule， twice a day， taking after breakfast and dinner. The treatment course was 12 weeks. Other drugs affected blood glucose and lipid metabolism， hepatic and renal functions （such as glucocorticoids） were forbidden. Clinical efficacy， blood glucose and lipid metabolism indicators（TC，TG， LDL-C， HDL-C，FPG， HbA1c， FINS， HOMA-IR）， hepatic and renal function indicators （ALT， AST， GGT， TBIL， Scr，BUN）， SOD， MDA， CRP， IL-6 before and after treatment and the incidence of adverse reactions in 2 groups were observed. RESULTS： The total effective rate in observation group was significantly higher than control group， with statistic significance （P＜0.05）. After treatment， FPG， HbA1c， FINS， HOMA-IR， TC， TG， LDL-C， ALT， AST， GGT， TBIL， MDA， CRP and IL-6 in 2 groups were significantly lower than before， and observation group was lower than control group， HDL-C and SOD were significantly higher than before， and observation group was higher than control group， with statistic significances （P＜0.05）. And there was no significant difference in the incidence of adverse reactions （P＞0.05）. CONCLUSIONS： Based on conventional treatment， Xuezhikang capsule shows superior efficacy in the treatment of post-menopause patients with type 2 diabetes and nonalcoholic fatty liver disease， it can improve insulin resistance， with good safety.